Elevation Oncology, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2025.

Location
Boston, MA
Fiscal year end
31 December
Latest financial report
15 May 2025

Quick Takeaways

  • Elevation Oncology, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q1 2025.
  • Headline metric: Return On Equity -78%.

What Changed

  • Return On Equity YoY change: <span class="text-green-600">+9%</span>.
  • Most recent SEC facts end date: 31 Mar 2025.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2025-03-31) highlights Return On Equity -78.3%, Return On Assets -50.2%, and Current Ratio 19.4x.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

17.1/100

Weak Confidence medium

Return On Equity

-78%

Metric score 0.0/100

Return On Assets

-50%

Metric score 0.0/100

Financial Health

Current Ratio
19.4x
Debt to Equity
0.55x

Strengths

Debt-to-equity

Watchpoints

Return On Equity, Return On Assets, and Current Ratio

Key metrics snapshot

Return On Equity

-78%

YoY: +9%

Industry median: -47% (n=218)

View history

Return On Assets

-50%

YoY: +19%

Industry median: -44% (n=217)

View history

Current Ratio

19.4x

YoY: -58%

Industry median: 3.67x (n=218)

View history

Debt-to-equity

0.55x

YoY: +2.1%

Industry median: 0.31x (n=169)

View history

NetIncomeLoss YoY

-22%

YoY:

Industry median: -12% (n=211)

View history

Profitability

Metric Latest value YoY change
Return On Equity -78% +9%
Return On Assets -50% +19%

Financial Health

Metric Latest value YoY change
Current Ratio 19.4x -58%
Debt-to-equity 0.55x +2.1%

Growth

Metric Latest value YoY change
NetIncomeLoss YoY -22%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 59,215,795 +8.4%
Common Stock, Shares, Outstanding 59,223,729 +15%
Common Stock, Value, Issued $6,000 +20%
Weighted Average Number of Shares Outstanding, Basic 59,173,854 +14%
Weighted Average Number of Shares Outstanding, Diluted 59,173,854 +14%

Additional Metrics

Metric Latest value YoY change
Research and Development Expense $29,462,000 +22%
General and Administrative Expense $16,213,000 +12%
Operating Income (Loss) $49,050,000 -27%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $47,951,000 -22%
Income Tax Expense (Benefit) $38,000 +5.6%
Earnings Per Share, Basic -1 -9.5%
Earnings Per Share, Diluted -1 -9.5%
Cash and Cash Equivalents, at Carrying Value $60,494,000 -33%
Marketable Securities, Current $20,165,000 +50%
Assets, Current $82,194,000 -24%
Property, Plant and Equipment, Net $29,000 -41%
Other Assets, Noncurrent $0 -100%
Assets $82,223,000 -25%
Accounts Payable, Current $492,000 +13%
Accrued Liabilities, Current $3,744,000 +97%
Liabilities, Current $4,236,000 +81%
Liabilities $35,489,000 +7.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax $11,000
Retained Earnings (Accumulated Deficit) $254,666,000 -23%
Stockholders' Equity Attributable to Parent $46,734,000 -38%
Liabilities and Equity $82,223,000 -25%
Share-based Payment Arrangement, Noncash Expense $987,000 +9.4%
Net Cash Provided by (Used in) Operating Activities $12,711,000 -33%
Net Cash Provided by (Used in) Investing Activities $23,758,000 +15%
Common Stock, Shares Authorized 500,000,000 0%
Common Stock, Shares, Issued 59,316,859 +15%
Common Stock, Par or Stated Value Per Share 0 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $11,030,000 -73%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60,494,000 -33%
Interest Paid, Excluding Capitalized Interest, Operating Activities $806,000 -9.1%
Depreciation $5,000 -50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $47,978,000 -22%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Authorized 10,000,000 0%
Additional Paid in Capital $301,507,000 +6.7%
Preferred Stock, Shares Outstanding 0
Share-based Payment Arrangement, Expense $4,365,000 +57%
Preferred Stock, Par or Stated Value Per Share 0 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY